These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 793487)

  • 1. Dialyzable transfer factor in the treatment of human osteosarcoma: an analytic review.
    Fudenberg HH
    Ann N Y Acad Sci; 1976; 277(00):545-57. PubMed ID: 793487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfer factor therapy in osteogenic sarcoma.
    Levin AS; Byers VS; Fudenberg HH; Wybran J; Hackett AJ; Johnston JO
    Trans Assoc Am Physicians; 1974; 87():153-8. PubMed ID: 4549141
    [No Abstract]   [Full Text] [Related]  

  • 3. Transfer factor versus combination chemotherapy: a preliminary report of a randomized postsurgical adjuvant treatment study in osteogenic sarcoma.
    Ivins JC; Ritts RE; Pritchard DJ; Gilchrist GS; Miller GC; Taylor WF
    Ann N Y Acad Sci; 1976; 277(00):558-74. PubMed ID: 1087138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discussion paper: tumor-specific transfer factor therapy in osteogenic sarcoma: a two-year study.
    Byers VS; Levin AS; LeCam L; Johnston JO; Hackett AJ
    Ann N Y Acad Sci; 1976; 277(00):621-7. PubMed ID: 1069564
    [No Abstract]   [Full Text] [Related]  

  • 5. Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor.
    Levin AS; Byers VS; Fudenberg HH; Wybran J; Hackett AJ; Johnston JO; Spitler LE
    J Clin Invest; 1975 Mar; 55(3):487-99. PubMed ID: 1078826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: New therapies for osteogenic sarcoma.
    Campbell CJ; Cohen J; Enneking WF
    J Bone Joint Surg Am; 1975 Mar; 57(2):143-4. PubMed ID: 1054022
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of osteogenic sarcoma at the Mayo Clinic.
    Ivins JC; Pritchard DJ
    Recent Results Cancer Res; 1976; (54):221-30. PubMed ID: 827796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines.
    Palmero A; Berger M; Venturi C; Ferrero I; Rustichelli D; Berta L; Frairia R; Madon E; Fagioli F
    Oncol Rep; 2006 Jan; 15(1):267-73. PubMed ID: 16328067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma.
    Tsuji H; Kawaguchi S; Wada T; Nagoya S; Inobe M; Yamashita T; Ishii S; Uede T
    Cancer Gene Ther; 2002 Sep; 9(9):747-55. PubMed ID: 12189524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of T-Cell Related Therapy for Osteosarcoma.
    Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The host immune response in human osteosarcoma.
    McMaster JH; Ferguson RJ; Weinert CR
    Clin Orthop Relat Res; 1975 Sep; (111):76-82. PubMed ID: 1057466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte and serum-mediated immunity in murine osteosarcoma.
    Miller CW; Fisher SJ
    J Bone Joint Surg Am; 1977 Oct; 59(7):981-3. PubMed ID: 269112
    [No Abstract]   [Full Text] [Related]  

  • 15. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer factor and other T cell products.
    Tsang KY; Fudenberg HH
    Springer Semin Immunopathol; 1986; 9(1):19-32. PubMed ID: 2425441
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant therapy for nonmetastatic osteogenic sarcoma: an evaluation of transfer factor versus combination chemotherapy.
    Gilchrist GS; Ivins JC; Ritts RE; Pritchard DJ; Taylor WF; Edmonson JM
    Cancer Treat Rep; 1978 Feb; 62(2):289-94. PubMed ID: 346219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of osteogenic sarcoma: a perspective based on the Mayo Clinic experience.
    Gilchrist GS; Pritchard DJ; Dahlin DC; Ivins JC; Taylor WF; Edmonson JH
    Natl Cancer Inst Monogr; 1981 Apr; (56):193-9. PubMed ID: 6946290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific cellular cytotoxicity to human sarcomas: evidence for a cell-mediated host immune response to a common sarcoma cell-surface antigen.
    Cohen AM; Ketcham AS; Morton DL
    J Natl Cancer Inst; 1973 Mar; 50(3):585-9. PubMed ID: 4513520
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy of osteosarcoma patients with virus-modified tumor cells.
    Green AA; Pratt C; Webster RG; Smith K
    Ann N Y Acad Sci; 1976; 277(00):396-411. PubMed ID: 1069558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.